Rehmannioside A inhibits the activity of CYP3A4, 2C9 and 2D6 in vitro

被引:0
作者
Wang, Congrong [1 ]
Zhou, Naixiang [2 ]
Li, Mingcui [3 ]
Chen, Haixia [4 ]
机构
[1] Shandong Publ Hlth Clin Ctr, Dept Pharm Ctr, Jinan, Peoples R China
[2] Jiyang Peoples Hosp Jinan, Dept Off, Jinan, Peoples R China
[3] Jinan Second Peoples Hosp, Dept Pharm, Jinan, Peoples R China
[4] Shandong Univ, Qilu Hosp, Dept Pharm, 7,West Wenhua Rd, Jinan 250012, Shandong, Peoples R China
关键词
Rehmannioside A; CYP450s; non-competitive inhibition; competitive inhibition; DRUG-DRUG INTERACTION; CYTOCHROME-P450; MECHANISM; ENZYMES; ACID;
D O I
10.1080/00498254.2024.2321969
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
To assess the effect of Rehmannioside A on CYP450s activity and to estimate its inhibitory properties.The effect of Rehmannioside A on the activity of major CYP450s in human liver microsomes (HLMs) was assessed with the corresponding substrates and marker reactions, and compared with a blank control and the respective inhibitors. Suppression of CYP3A4, 2C9 and 2D6 was assessed by the dose-dependent assay and fitted with non-competitive or competitive inhibition models. The inhibition of CYP3A4 was determined in a time-dependent manner.Rehmannioside A suppressed the activity of CYP3A4, 2C9, and 2D6 with IC50 values of 10.08, 12.62, and 16.43 mu M, respectively. Suppression of CYP3A4 was fitted to a non-competitive model with Ki value of 5.08 mu M, whereas CYP2C9 and 2D6 were fitted to a competitive model with Ki values of 6.25 and 8.14 mu M. Additionally, the inhibitory effect on CYP3A4 was time-dependent with KI value of 8.47 mu M-1 and a Kinact of 0.048 min-1.In vitro suppression of CYP3A, 2C9 and 2D6 by Rehmannioside A indicated that Rehmannioside A or its source herbs may interact with drugs metabolised by these CYP450s, which could guide the clinical application.
引用
收藏
页码:195 / 200
页数:6
相关论文
共 31 条
  • [1] Pharmacogenetics of drug-drug interaction and drug-drug-gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6
    Bahar, Muh Akbar
    Setiawan, Didik
    Hak, Eelko
    Wilffert, Bob
    [J]. PHARMACOGENOMICS, 2017, 18 (07) : 701 - 743
  • [2] Decoding active components in a formulation of multiple herbs for treatment of psoriasis based on three cell lines fishing and liquid chromatography-mass spectrometry analysis
    Chen, Lingxiao
    Chen, Haiming
    Lu, Yue
    Han, Ling
    Wang, Shenfei
    Liu, Meiting
    Li, Xiong
    Zhao, Jing
    Lu, Chuanjian
    Li, Shaoping
    [J]. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2020, 186
  • [3] Prediction of Cytochrome P450 Inhibition Using a Deep Learning Approach and Substructure Pattern Recognition
    Chen, Zhaoyang
    Zhang, Le
    Zhang, Pei
    Guo, Huizhu
    Zhang, Ruiqiu
    Li, Ling
    Li, Xiao
    [J]. JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2023, 64 (07) : 2528 - 2538
  • [4] Pharmacokinetics, safety and tolerability of valbenazine in Korean CYP2D6 normal and intermediate metabolizers
    Chung, Woo Kyung
    Hwang, Inyoung
    Kim, Byungwook
    Jung, Jihyun
    Yu, Kyung-Sang
    Jang, In-Jin
    Oh, Jaeseong
    [J]. CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2023, 16 (03): : 512 - 523
  • [5] Rehmannioside A improves cognitive impairment and alleviates ferroptosis via activating PI3K/AKT/Nrf2 and SLC7A11/GPX4 signaling pathway after ischemia
    Fu, Chen
    Wu, Yifan
    Liu, Shaojiao
    Luo, Chaoqin
    Lu, Yuqiao
    Liu, Menghan
    Wang, Lingfeng
    Zhang, Yunling
    Liu, Xuemei
    [J]. JOURNAL OF ETHNOPHARMACOLOGY, 2022, 289
  • [6] Diverse reactions catalyzed by cytochrome P450 and biosynthesis of steroid hormone
    Fujiyama, Keisuke
    Hino, Tomoya
    Nagano, Shingo
    [J]. BIOPHYSICS AND PHYSICOBIOLOGY, 2022, 19
  • [7] Identification of Kaurane-Type Diterpenes as Inhibitors of Leishmania Pteridine Reductase I
    Herrera-Acevedo, Chonny
    Flores-Gaspar, Areli
    Scotti, Luciana
    Mendonca-Junior, Francisco Jaime Bezerra
    Scotti, Marcus Tullius
    Coy-Barrera, Ericsson
    [J]. MOLECULES, 2021, 26 (11):
  • [8] Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions between Elexacaftor/Tezacaftor/Ivacaftor and Tacrolimus in Lung Transplant Recipients
    Hong, Eunjin
    Carmanov, Eugeniu
    Shi, Alan
    Chung, Peter S.
    Rao, Adupa P.
    Forrester, Kevin
    Beringer, Paul M.
    [J]. PHARMACEUTICS, 2023, 15 (05)
  • [9] Exploration of cytochrome P450 inhibition mediated drug-drug interaction potential of kratom alkaloids
    Kamble, Shyam H.
    Sharma, Abhisheak
    King, Tamara I.
    Berthold, Erin C.
    Leon, Francisco
    Meyer, P. Katharina L.
    Kanumuri, Siva Rama Raju
    McMahon, Lance R.
    McCurdy, Christopher R.
    Avery, Bonnie A.
    [J]. TOXICOLOGY LETTERS, 2020, 319 : 148 - 154
  • [10] Downregulation of CYP39A1 Serves as a Novel Biomarker in Hepatocellular Carcinoma with Worse Clinical Outcome
    Li, Dan
    Yu, Tao
    Hu, Junjie
    Wu, Jie
    Feng, Shi
    Xu, Qingxue
    Zhu, Hua
    Zhang, Xu
    Zhang, Yonggang
    Zhou, BenHong
    Gu, Lijuan
    Zeng, Zhi
    [J]. OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2021, 2021